Delivery Order SPE2DB20D3104-SPE2DB24FV8J1

Award Date 7/22/24
Potential Completion Date 7/23/24
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, in the amount of $1,328.12. The contract is for the supply of Micardis HCT 80-25 mg tablet units, a cardiovascular medication, to support military healthcare programs. The contract has a period of performance through May 13, 2024 and is a firm fixed-price delivery order. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,366.20, is for the provision of MICARDIS HCT 40-12.5 MG TABLET UD 30S, a pharmaceutical product, to support military healthcare programs. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4557775889 - MICARDIS HCT 80-25 MG TABLET UD 30S. The contract has a firm fixed price of $4,094.38 and an ultimate completion date of July 13, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a...
This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,190.04 firm fixed-price contract is for the delivery of Micardis HCT 80-25 mg tablets, with a performance period ending on March 6, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a delivery order contract awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,521.63 fixed-price contract is for the delivery of MICARDIS HCT 40-12.5 mg tablets through November 30, 2023. It is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical to provide a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,353 firm fixed-price contract is for the delivery of 4,566,210,065 units of the medication Micardis HCT 80-25 mg tablet, with an ultimate completion date of October 28, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $7,116.14 and is for the delivery of Micardis HCT 40-12.5 mg tablets. The award has a completion date of June 5, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,949.78, is for the delivery of MICARDIS HCT 40-12.5 MG TABLET UD 30S, a cardiovascular medication. The contract has an ultimate completion date of February 21, 2024 and is a Firm Fixed Price contract. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,635.18, is for the delivery of Micardis HCT 40-12.5 mg tablets to support federal healthcare programs. The contract has an ultimate completion date of June 18, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,862.19, is for the delivery of Micardis HCT 40-12.5 mg tablets to support federal healthcare programs. The contract is a Firm Fixed Price Delivery Order with a period of performance through November 3, 2023. The contract has no set-aside designation, indicating open competition....
  • SPE2DB20D3104
    Indefinite Delivery Contract
  • SPE2DB20D3104-SPE2DB24FV8J1
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,435.70, is for the delivery of Micardis HCT 40-12.5 mg tablets. The contract has a firm fixed price pricing type and an ultimate completion date of July 23, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This delivery order contract does not have a set-aside designation, indicating open competition. The contract supports the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

Generated 2/27/25, 11:01 AM